


Hikal Limited : Q1FY20 Results

- ✓ Revenue of Rs. 403 Crores; a YoY growth of 24%
- ✓ PBT of Rs. 37 Crores; a YoY growth of 57%

Mumbai, August 1, 2019: Hikal Ltd, a preferred long-term partner for leading global life sciences companies, announced its financial results for the quarter ended 30th June, 2019

Highlights for quarter ended 30th June, 2019



Segmental Performance for the quarter ended 30th June, 2019

- **Crop Protection sales up 34% to Rs. 199 crore** as compared to Rs. 149 crore in the corresponding period of the previous year
- **Pharmaceutical sales up 15% to Rs. 204 crore** as compared to Rs. 177 crore in the corresponding period of the previous year

Commenting on the results, Jai Hiremath, Chairman & Managing Director, Hikal Ltd. said,

“We have started the financial year on a positive note with both our divisions reporting growth. Our Revenues and Net Profit for quarter were Rs. 403 crore and Rs. 25 crore representing a growth of 24% and 58% respectively.

Both our Crop Protection and Pharmaceutical divisions have grown by 34% & 15% as compared to the previous quarter of last financial year on increased orders of existing and new products.

Our EBITDA margins were impacted due to change in product mix and increase in environmental compliance costs. We expect margins to stabilise next quarter with an improvement in the second half of the financial year.

Our focus is on executing the new projects that we have invested in significantly in both divisions. These will bring additional revenues and a margin expansion to our business. “



About Hikal Limited

Hikal is a reliable long-term partner to companies in the Pharmaceuticals, Crop Protection, and Specialty Chemicals industry. The company is in the business of supplying research services, active ingredients and intermediates, manufactured using stringent global quality standards, for its global customers. Hikal's advanced manufacturing facilities have been inspected and approved by leading multinational companies in the Crop protection and Pharmaceutical sectors. The Crop protection facilities are located at Taloja and Mahad (Maharashtra). Hikal's R&T facilities are located at Pune. The Pharmaceutical manufacturing facilities are situated in Jigani (Bengaluru) and Panoli (Gujarat). Hikal is the first Indian life-sciences company to receive the Responsible Care® certification governed by the International Council of Chemical Associations (ICCA).

Safe Harbor Statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further information, please contact

Company :

Hikal Limited

CIN: L24200MH1988PTC048028

Mr. Anish Swadi

anish_swadi@hikal.com

www.hikal.com

Investor Relations Advisors :

Strategic Growth Advisors Pvt. Ltd.

CIN: U74140MH2010PTC204285

Ms. Payal Dave / Mr. Jigar Kavaiya

payal.dave@sgapl.net / jigar.kavaiya@sgapl.net

+91 9819916314 / +91 9920602034

www.sgapl.net